Nations Financial Group Inc. IA ADV Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Nations Financial Group Inc. IA ADV raised its position in Pfizer Inc. (NYSE:PFE) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,583 shares of the biopharmaceutical company’s stock after acquiring an additional 1,749 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Pfizer were worth $1,543,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Clifford Swan Investment Counsel LLC raised its position in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $255,000. KLCM Advisors Inc. boosted its stake in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares in the last quarter. Finally, Farmers Trust Co. grew its stake in Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after buying an additional 4,410 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

PFE stock traded up $0.19 on Friday, hitting $28.88. 22,589,127 shares of the company were exchanged, compared to its average volume of 44,974,800. The stock has a market capitalization of $163.65 billion, a price-to-earnings ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63. The business’s fifty day moving average is $27.27 and its two-hundred day moving average is $27.94. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 EPS. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.